Table 20Summary results for DFS in Knoop, Bentzen, Nielsen, et al. (2001)

HER2 StatusTreatment group5-year DFS
(% ± SE)
10-year DFS
(% ± SE)
Log rank p valuep value with Bonferroni correction
Negative/low-positive (n=1,005) Tamoxifen 57% (±2) 34% (±2) .0001.0006
Control43% (±2)26% (±2)
High-positive
(n=52)
Tamoxifen63% (±11)37% (±12) .5.5
Control41% (±9)35% (±8)

Abbreviations: DFS: disease-free survival; SE: standard error;

From: 3, Results and Conclusions

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.